Kavitha Hubbard, MD
Nephrology · Gilroy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 1 carrier
- Offices
- 2
Offices
2 locations · Central Coast Nephrology Medical Corporation · 11 clinicians in this group
Hospitals listed: Community Hospital of the Monterey Peninsula · Hazel Hawkins Memorial Hospital · Salinas Valley Health Medical Center. That is not proof they admit you there this week.
Plans that list them
13 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hubbard’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A79279 · Current
Licensed to practise in California · since 2002 · expires 2028-02-29 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Salinas Valley Health Medical CenterSalinas, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Salinas Valley Memorial Healthcare SystemPatients rate it 4 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.247, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Salinas Valley Health Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.247 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.32 (0.34 to 2.3) · 1,159 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.68 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.42 (143.23 to 253.6) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 203 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 536 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 239 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,377 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,593 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,999 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.97 (1.83 to 6.1) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.7 (0.16 to 3.24) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.87 to 3.76) · 1,325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.78 (3.73 to 15.83) · 461 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.23 (1.52 to 8.95) · 453 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 279 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.48 (0 to 1.11) · 6,011 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.487 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.082 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.432 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.373 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 197 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 491 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 224 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8 · 660 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 569 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 485 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.2 to 8.4) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 197 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 489 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,383 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$502,488
Medicare paid this office $502,488 for 301 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 182 | $22,695 | $57 |
| Injection, denosumab, 1 mg | 14 | $15,765 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $9,120 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $4,561 | $56 |
| New patient visit (45+ min) | 29 | $3,856 | $133 |
See all 16 services
| Return visit (30+ min) | 182 | $22,695 | $57 |
| Injection, denosumab, 1 mg | 14 | $15,765 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $9,120 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $4,561 | $56 |
| New patient visit (45+ min) | 29 | $3,856 | $133 |
| Complete ultrasound scan behind abdominal cavity | 25 | $2,397 | $92 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14 | $2,297 | $0 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $2,275 | $108 |
| Influenza vaccine split virus, preservative free | 23 | $1,852 | $81 |
| Injection of drug or substance under skin or into muscle | 54 | $1,795 | $12 |
| Insertion of needle into vein for collection of blood sample | 68 | $1,289 | $9 |
| Kidney function blood test panel | 62 | $929 | $8 |
| Administration of influenza virus vaccine | 24 | $803 | $33 |
| Administration of chemotherapy into vein, each additional hour | 15 | $697 | $23 |
| Injection of drug or substance into vein | 11 | $583 | $32 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $327 | $20 |
Who their Medicare patients are
301 Original Medicare patients in 2024. Average age 76 · Under 65 10% · 85 and older 17% · Women 61% · Also on Medicaid 44% · Health risk score 1.91. At or below the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 60% · Coronary heart disease 34% · Heart failure 28% · Atrial fibrillation 17% · Depression 17% · COPD 15% · Cancer 10% · Dementia 9% · Stroke 7%.
The office billed $1,285,928, Medicare allowed $642,445 and paid $502,488; for 39,192 services of 51 kinds; $459,227 of it was for drugs given in the office and $43,261 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 301 | 39,192 | 76 | 1.91 | $1,285,928 | $502,488 |
| 2023 | 334 | 32,986 | 76 | 1.73 | $1,146,140 | $556,350 |
| 2022 | 396 | 31,152 | 75 | 1.81 | $1,204,539 | $530,691 |
| 2021 | 216 | 9,757 | 76 | 1.79 | $331,232 | $146,410 |
| 2020 | 207 | 8,801 | 76 | 1.85 | $229,517 | $93,365 |
| 2019 | 226 | 7,490 | 75 | 1.81 | $291,940 | $122,787 |
| 2018 | 306 | 20,944 | 74 | 2.12 | $451,488 | $191,414 |
| 2017 | 441 | 20,679 | 74 | 2.74 | $569,962 | $254,682 |
| 2016 | 422 | 20,709 | 74 | 2.25 | $557,753 | $237,300 |
| 2015 | 396 | 20,226 | 73 | 2.58 | $460,416 | $201,271 |
| 2014 | 296 | 18,725 | 73 | 2.80 | $304,176 | $135,400 |
| 2013 | 82 | 163 | 73 | 6.06 | $22,741 | $11,201 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Injection, inclisiran, 1 mg | 11 | $40,075 | None |
| Injection, denosumab, 1 mg | 33 | $38,584 | None |
| Return visit (30+ min) | 189 | $24,857 | $68 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 23 | $8,223 | None |
| New patient visit (45+ min) | 45 | $5,486 | $122 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $3,581 | $56 |
| Complete ultrasound scan behind abdominal cavity | 32 | $3,043 | $92 |
| Injection of drug or substance under skin or into muscle | 84 | $2,397 | $12 |
| Insertion of needle into vein for collection of blood sample | 67 | $1,033 | $8 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $772 | $27 |
| Kidney function blood test panel | 57 | $737 | $9 |
| Short return visit (20+ min) | 21 | $720 | $33 |
| Administration of influenza virus vaccine | 11 | $305 | $28 |
| Red blood cell concentration measurement | 17 | $104 | $2 |
| Blood count, hemoglobin | 17 | $104 | $2 |
2022: 18 services
| Injection, denosumab, 1 mg | 30 | $32,684 | None |
| Return visit (30+ min) | 151 | $28,090 | $99 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 53 | $12,882 | None |
| New patient visit (45+ min) | 69 | $8,887 | $129 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14 | $5,150 | $1 |
| Complete ultrasound scan behind abdominal cavity | 53 | $5,109 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $4,798 | $61 |
| Short return visit (20+ min) | 58 | $4,615 | $63 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $4,011 | $122 |
| Injection of drug or substance under skin or into muscle | 91 | $2,783 | $12 |
| Administration of chemotherapy into vein, each additional hour | 19 | $1,372 | $26 |
| New patient visit (30+ min) | 15 | $1,312 | $87 |
| Kidney function blood test panel | 92 | $1,009 | $9 |
| Influenza vaccine split virus, preservative free | 12 | $822 | $69 |
| New patient visit (15+ min) | 11 | $519 | $47 |
| Insertion of needle into vein for collection of blood sample | 113 | $426 | $3 |
| Administration of influenza virus vaccine | 12 | $335 | $28 |
| Blood count, hemoglobin | 39 | $154 | $2 |
2021: 11 services
| Return visit (30+ min) | 100 | $21,908 | $97 |
| Injection, denosumab, 1 mg | 16 | $15,637 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 40 | $5,476 | None |
| Complete ultrasound scan behind abdominal cavity | 33 | $3,147 | $95 |
| Short return visit (20+ min) | 21 | $2,179 | $73 |
| New patient visit (15+ min) | 26 | $1,555 | $60 |
| Injection of drug or substance under skin or into muscle | 59 | $1,272 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $1,000 | $62 |
| Kidney function blood test panel | 54 | $531 | $9 |
| Insertion of needle into vein for collection of blood sample | 56 | $198 | $3 |
| Blood count, hemoglobin | 18 | $59 | $2 |
2020: 13 services
| Injection, denosumab, 1 mg | 35 | $33,861 | None |
| Return visit (30+ min) | 105 | $17,193 | $79 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 27 | $4,284 | None |
| Complete ultrasound scan behind abdominal cavity | 17 | $1,619 | $95 |
| Short return visit (20+ min) | 21 | $1,474 | $61 |
| Short return visit | 33 | $1,034 | $29 |
| Injection of drug or substance under skin or into muscle | 65 | $1,003 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $907 | $60 |
| Influenza vaccine split virus, preservative free | 11 | $671 | $61 |
| Kidney function blood test panel | 49 | $447 | $9 |
| Administration of influenza virus vaccine | 13 | $233 | $18 |
| Insertion of needle into vein for collection of blood sample | 52 | $169 | $3 |
| Blood count, hemoglobin | 16 | $45 | $2 |
2019: 11 services
| Injection, denosumab, 1 mg | 35 | $33,213 | None |
| Return visit (30+ min) | 134 | $25,141 | $81 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 28 | $5,906 | None |
| Complete ultrasound scan behind abdominal cavity | 21 | $1,919 | $91 |
| Short return visit (20+ min) | 21 | $1,351 | $48 |
| Injection of drug or substance under skin or into muscle | 69 | $1,216 | $12 |
| Short return visit | 36 | $1,114 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $844 | $56 |
| Kidney function blood test panel | 41 | $435 | $9 |
| Insertion of needle into vein for collection of blood sample | 49 | $162 | $3 |
| Blood count, hemoglobin | 12 | $39 | $3 |
2018: 14 services
| Injection, denosumab, 1 mg | 52 | $49,910 | None |
| Return visit (30+ min) | 163 | $26,464 | $77 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 18 | $5,816 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $5,494 | $1 |
| Short return visit (20+ min) | 57 | $3,792 | $53 |
| Complete ultrasound scan behind abdominal cavity | 24 | $2,239 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $2,124 | $61 |
| Short return visit | 52 | $1,872 | $32 |
| Injection of drug or substance under skin or into muscle | 71 | $1,739 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,395 | $63 |
| New patient visit (30+ min) | 14 | $1,157 | $83 |
| Kidney function blood test panel | 70 | $830 | $11 |
| Insertion of needle into vein for collection of blood sample | 85 | $279 | $3 |
| Blood count, hemoglobin | 14 | $46 | $3 |
2017: 14 services
| Injection, denosumab, 1 mg | 84 | $74,340 | None |
| Return visit (30+ min) | 159 | $25,149 | $75 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 28 | $11,535 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $8,373 | $59 |
| Short return visit (20+ min) | 68 | $4,849 | $51 |
| Injection of drug or substance under skin or into muscle | 115 | $4,190 | $21 |
| Complete ultrasound scan behind abdominal cavity | 44 | $4,024 | $89 |
| Short return visit | 84 | $2,814 | $30 |
| New patient visit (15+ min) | 46 | $2,693 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $2,158 | $57 |
| Kidney function blood test panel | 97 | $1,307 | $12 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $1,000 | $83 |
| Insertion of needle into vein for collection of blood sample | 104 | $359 | $3 |
| Blood count, hemoglobin | 19 | $121 | $3 |
2016: 15 services
| Injection, denosumab, 1 mg | 99 | $74,551 | None |
| Return visit (30+ min) | 152 | $24,511 | $76 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 34 | $10,595 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $4,679 | $61 |
| Short return visit (20+ min) | 53 | $4,383 | $54 |
| Injection of drug or substance under skin or into muscle | 136 | $4,304 | $21 |
| Complete ultrasound scan behind abdominal cavity | 43 | $3,860 | $90 |
| Short return visit | 99 | $3,052 | $30 |
| New patient visit (15+ min) | 45 | $2,415 | $54 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $1,997 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,493 | $115 |
| Kidney function blood test panel | 112 | $1,485 | $11 |
| Insertion of needle into vein for collection of blood sample | 120 | $406 | $3 |
| Blood count, hemoglobin | 24 | $83 | $3 |
| Manual urinalysis test with examination using microscope, non-automated | 15 | $63 | $4 |
2015: 14 services
| Injection, denosumab, 1 mg | 63 | $47,901 | None |
| Return visit (30+ min) | 138 | $23,541 | $84 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 41 | $11,551 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $7,061 | $61 |
| Complete ultrasound scan behind abdominal cavity | 69 | $6,533 | $95 |
| Short return visit (20+ min) | 77 | $5,660 | $52 |
| New patient visit (30+ min) | 70 | $4,856 | $69 |
| Injection of drug or substance under skin or into muscle | 106 | $4,049 | $21 |
| Short return visit | 65 | $2,377 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $2,265 | $57 |
| New patient visit (15+ min) | 36 | $2,068 | $57 |
| Kidney function blood test panel | 94 | $1,297 | $12 |
| Insertion of needle into vein for collection of blood sample | 107 | $417 | $3 |
| Blood count, hemoglobin | 31 | $149 | $3 |
2014: 16 services
| Injection, denosumab, 1 mg | 33 | $22,394 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 74 | $9,779 | $62 |
| Return visit (30+ min) | 55 | $7,554 | $87 |
| New patient visit (30+ min) | 79 | $6,923 | $88 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 35 | $6,049 | None |
| Complete ultrasound scan behind abdominal cavity | 43 | $4,841 | $113 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $3,230 | $1 |
| Short return visit (20+ min) | 29 | $2,422 | $59 |
| Injection of drug or substance under skin or into muscle | 70 | $2,111 | $21 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,000 | $118 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $1,336 | $53 |
| Short return visit | 34 | $1,207 | $35 |
| Kidney function blood test panel | 58 | $713 | $12 |
| Injection of drug or substance into vein | 11 | $612 | $47 |
| Insertion of needle into vein for collection of blood sample | 74 | $241 | $3 |
| Blood count, hemoglobin | 21 | $79 | $3 |
2013: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $7,997 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,544 | $116 |
Medicaid work
$2,521 in 2024
Medicaid paid $2,521 for 62 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 47 | $1,819 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 15 | $701 |
| 2024 | 62 | 2 | 19 | $2,521 |
| 2023 | 240 | 1 | 37 | $11,581 |
| 2022 | 218 | 4 | 23 | $7,704 |
| 2021 | 113 | 1 | 19 | $4,060 |
| 2020 | 78 | 1 | 20 | $2,762 |
| 2019 | 119 | 1 | 23 | $2,552 |
| 2018 | 152 | 2 | 26 | $2,270 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 240 | $11,581 |
2022
| Return visit (30+ min) | 165 | $6,835 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $452 |
| Short return visit (20+ min) | 14 | $417 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 18 | $0 |
2021
| Return visit (30+ min) | 113 | $4,060 |
2020
| Return visit (30+ min) | 78 | $2,762 |
2019
| Return visit (30+ min) | 119 | $2,552 |
2018
| Return visit (30+ min) | 140 | $2,160 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 12 | $110 |
Drugs they prescribed that Part D paid
$112,347
Pharmacies billed $112,347 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 956) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
823 generic and 133 brand-name prescriptions · $112,347 in drug cost · 19 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Velphoro | 15 | $31,772 | $2,118 |
| Kerendia | 22 | $27,704 | $1,259 |
| Farxiga | 15 | $16,999 | $1,133 |
| Jardiance | 14 | $7,518 | $537 |
| Furosemide | 216 | $1,731 | $8 |
See all 19 drugs
| Velphoro | 15 | $31,772 | $2,118 |
| Kerendia | 22 | $27,704 | $1,259 |
| Farxiga | 15 | $16,999 | $1,133 |
| Jardiance | 14 | $7,518 | $537 |
| Furosemide | 216 | $1,731 | $8 |
| Calcitriol | 149 | $1,660 | $11 |
| Sevelamer Carbonate | 30 | $1,572 | $52 |
| Bumetanide | 29 | $1,110 | $38 |
| Losartan | 77 | $938 | $12 |
| Febuxostat | 12 | $693 | $58 |
| Hydralazine | 33 | $425 | $13 |
| Amlodipine Besylate | 67 | $417 | $6 |
| Chlorthalidone | 18 | $327 | $18 |
| Lisinopril | 34 | $293 | $9 |
| Atorvastatin | 11 | $238 | $22 |
| Allopurinol | 14 | $172 | $12 |
| Tamsulosin | 11 | $169 | $15 |
| Spironolactone | 19 | $163 | $9 |
| Benazepril | 11 | $48 | $4 |
Year by year
| 2024 | 956 | 173 | 0% (0) | 14% | $112,347 |
| 2023 | 909 | 164 | 0% (0) | 17% | $161,761 |
| 2022 | 700 | 143 | 0% (0) | 14% | $47,502 |
| 2021 | 590 | 92 | 0% (0) | 17% | $59,531 |
| 2020 | 533 | 80 | None | 19% | $46,032 |
| 2019 | 691 | 97 | None | 14% | $44,319 |
| 2018 | 836 | 121 | None | 12% | $32,038 |
| 2017 | 769 | 114 | None | 21% | $30,608 |
| 2016 | 676 | 110 | None | 26% | $38,635 |
| 2015 | 583 | 94 | None | None | $37,729 |
| 2014 | 157 | 35 | 0% (0) | 25% | $8,292 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Velphoro | 20 | $58,014 | $2,901 |
| Kerendia | 42 | $40,613 | $967 |
| Farxiga | 31 | $22,546 | $727 |
| Calcitriol | 150 | $2,101 | $14 |
| Furosemide | 212 | $1,987 | $9 |
| Bumetanide | 43 | $1,971 | $46 |
| Losartan | 72 | $1,711 | $24 |
| Sevelamer Carbonate | 16 | $1,417 | $89 |
| Amlodipine Besylate | 63 | $893 | $14 |
| Hydralazine | 38 | $891 | $23 |
| Chlorthalidone | 13 | $515 | $40 |
| Tamsulosin | 16 | $453 | $28 |
| Lisinopril | 30 | $443 | $15 |
| Allopurinol | 19 | $323 | $17 |
| Vitamin D2 | 11 | $42 | $4 |
2022: 13 drugs
| Veltassa | 18 | $17,977 | $999 |
| Calcitriol | 111 | $2,194 | $20 |
| Bumetanide | 32 | $1,739 | $54 |
| Sevelamer Carbonate | 16 | $1,575 | $98 |
| Losartan | 53 | $1,206 | $23 |
| Furosemide | 192 | $1,116 | $6 |
| Hydralazine | 28 | $624 | $22 |
| Chlorthalidone | 15 | $459 | $31 |
| Amlodipine Besylate | 46 | $348 | $8 |
| Allopurinol | 21 | $269 | $13 |
| Tamsulosin | 22 | $230 | $10 |
| Lisinopril | 22 | $95 | $4 |
| Vitamin D2 | 12 | $59 | $5 |
2021: 11 drugs
| Veltassa | 27 | $27,109 | $1,004 |
| Sevelamer | 11 | $9,457 | $860 |
| Calcitriol | 136 | $2,231 | $16 |
| Calcium Acetate | 21 | $1,889 | $90 |
| Sevelamer Carbonate | 13 | $1,730 | $133 |
| Chlorthalidone | 22 | $845 | $38 |
| Furosemide | 138 | $821 | $6 |
| Hydralazine | 29 | $611 | $21 |
| Losartan | 22 | $415 | $19 |
| Allopurinol | 25 | $277 | $11 |
| Amlodipine Besylate | 32 | $270 | $8 |
2020: 11 drugs
| Veltassa | 29 | $26,800 | $924 |
| Ethacrynic Acid | 11 | $5,575 | $507 |
| Calcitriol | 142 | $3,339 | $24 |
| Calcium Acetate | 23 | $2,216 | $96 |
| Chlorthalidone | 21 | $969 | $46 |
| Furosemide | 111 | $829 | $7 |
| Hydralazine | 30 | $761 | $25 |
| Losartan | 24 | $305 | $13 |
| Amlodipine Besylate | 37 | $246 | $7 |
| Lisinopril | 11 | $93 | $8 |
| Terazosin | 11 | $86 | $8 |
2019: 13 drugs
| Veltassa | 27 | $23,286 | $862 |
| Calcitriol | 202 | $3,853 | $19 |
| Calcium Acetate | 29 | $1,779 | $61 |
| Hydralazine | 49 | $1,234 | $25 |
| Furosemide | 130 | $912 | $7 |
| Chlorthalidone | 23 | $822 | $36 |
| Pravastatin | 28 | $697 | $25 |
| Amlodipine Besylate | 36 | $269 | $7 |
| Losartan | 26 | $229 | $9 |
| Lisinopril | 22 | $204 | $9 |
| Allopurinol | 12 | $178 | $15 |
| Atorvastatin | 11 | $151 | $14 |
| Terazosin | 16 | $125 | $8 |
2018: 14 drugs
| Veltassa | 16 | $11,844 | $740 |
| Calcitriol | 234 | $4,691 | $20 |
| Ethacrynic Acid | 17 | $4,087 | $240 |
| Calcium Acetate | 19 | $1,802 | $95 |
| Furosemide | 184 | $1,194 | $6 |
| Hydralazine | 62 | $1,159 | $19 |
| Pravastatin | 49 | $1,153 | $24 |
| Chlorthalidone | 22 | $956 | $43 |
| Atorvastatin | 15 | $201 | $13 |
| Lisinopril | 33 | $199 | $6 |
| Amlodipine Besylate | 36 | $196 | $5 |
| Terazosin | 18 | $150 | $8 |
| Losartan | 21 | $140 | $7 |
| Allopurinol | 13 | $101 | $8 |
2017: 14 drugs
| Veltassa | 19 | $13,289 | $699 |
| Calcitriol | 187 | $3,430 | $18 |
| Pravastatin | 52 | $1,538 | $30 |
| Chlorthalidone | 19 | $1,031 | $54 |
| Furosemide | 193 | $870 | $5 |
| Hydralazine | 45 | $778 | $17 |
| Potassium Chloride | 11 | $382 | $35 |
| Lisinopril | 55 | $313 | $6 |
| Amlodipine Besylate | 34 | $281 | $8 |
| Doxazosin Mesylate | 11 | $242 | $22 |
| Losartan | 21 | $190 | $9 |
| Atorvastatin | 13 | $176 | $14 |
| Allopurinol | 12 | $162 | $14 |
| Terazosin | 15 | $87 | $6 |
2016: 11 drugs
| Veltassa | 16 | $10,272 | $642 |
| Pravastatin | 82 | $2,110 | $26 |
| Calcitriol | 103 | $1,244 | $12 |
| Furosemide | 196 | $758 | $4 |
| Lisinopril | 91 | $503 | $6 |
| Hydralazine | 14 | $342 | $24 |
| Losartan | 22 | $190 | $9 |
| Amlodipine Besylate | 30 | $173 | $6 |
| Terazosin | 19 | $165 | $9 |
| Carvedilol | 14 | $78 | $6 |
| Ranitidine | 13 | $58 | $4 |
2015: 13 drugs
| Sensipar | 14 | $17,958 | $1,283 |
| Calcium Acetate | 11 | $1,224 | $111 |
| Pravastatin | 34 | $1,092 | $32 |
| Furosemide | 160 | $609 | $4 |
| Calcitriol | 51 | $459 | $9 |
| Hydralazine | 15 | $400 | $27 |
| Amlodipine Besylate | 52 | $283 | $5 |
| Lisinopril | 58 | $280 | $5 |
| Cartia Xt | 11 | $272 | $25 |
| Losartan | 21 | $233 | $11 |
| Terazosin | 23 | $206 | $9 |
| Famotidine | 11 | $59 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $45 | $4 |
2014: 4 drugs
| Enalapril Maleate | 11 | $183 | $17 |
| Furosemide | 52 | $163 | $3 |
| Terazosin | 15 | $91 | $6 |
| Amlodipine Besylate | 12 | $68 | $6 |
Money from drug and device companies
$894 in 2025
| 2025 | 14 | 38 | None | $894 |
| 2024 | 9 | 37 | None | $774 |
| 2023 | 15 | 45 | None | $847 |
| 2022 | 13 | 34 | None | $642 |
| 2021 | 7 | 16 | None | $321 |
| 2020 | 4 | 7 | None | $140 |
| 2019 | 3 | 4 | None | $77 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Krystexxa | $138 | 8 payments
|
| Travere Therapeutics | None | $126 | 6 payments
|
| Calliditas Therapeutics US | Tarpeyo | $114 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $90 | 2 payments
|
| Ardelyx | Ibsrela | $73 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $66 | 3 payments
|
See all 38 published payments
| Amgen | Meals · 2025-12-09 | Krystexxa | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-02 | Kerendia | $18 |
| Amgen | Meals · 2025-11-20 | Tavneos | $20 |
| Amgen | Meals · 2025-11-13 | Krystexxa | $9 |
| Novartis Pharmaceuticals | Meals · 2025-11-11 | Vanrafia | $18 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-06 | Kerendia | $18 |
| Amgen | Meals · 2025-11-04 | Krystexxa | $18 |
| Ardelyx | Meals · 2025-10-28 | Ibsrela | $28 |
| Akebia Therapeutics | Meals · 2025-10-14 | Vafseo | $29 |
| Amgen | Meals · 2025-10-07 | Tavneos | $27 |
| Amgen | Meals · 2025-10-02 | Krystexxa | $8 |
| Calliditas Therapeutics US | Meals · 2025-10-02 | Tarpeyo | $36 |
| Ardelyx | Meals · 2025-09-30 | Ibsrela | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-23 | Kerendia | $30 |
| Vifor Pharma | Meals · 2025-09-18 | Veltassa | $29 |
| Scpharmaceuticals | Meals · 2025-08-07 | Furoscix | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | None | $69 |
| Novartis Pharmaceuticals | Meals · 2025-06-26 | Fabhalta | $27 |
| Calliditas Therapeutics US | Meals · 2025-06-12 | Tarpeyo | $33 |
| Kyowa Kirin | Meals · 2025-05-22 | Crysvita | $20 |
| Travere Therapeutics | Meals · 2025-05-22 | None | $20 |
| Amgen | Meals · 2025-05-06 | Krystexxa | $12 |
| Travere Therapeutics | Meals · 2025-04-23 | None | $26 |
| Akebia Therapeutics | Meals · 2025-04-22 | Vafseo | $23 |
| Amgen | Meals · 2025-04-17 | Tavneos | $16 |
| ANI Pharmaceuticals | Meals · 2025-04-16 | Purified Cortrophin Gel | $20 |
| Ardelyx | Meals · 2025-04-01 | Ibsrela | $22 |
| Calliditas Therapeutics US | Meals · 2025-03-28 | Tarpeyo | $24 |
| Travere Therapeutics | Meals · 2025-03-11 | None | $2 |
| Travere Therapeutics | Meals · 2025-03-11 | None | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-06 | Farxiga | $22 |
| Travere Therapeutics | Meals · 2025-03-05 | None | $24 |
| Otsuka America Pharmaceutical | Meals · 2025-02-13 | Jynarque | $22 |
| Mallinckrodt Hospital Products | Meals · 2025-02-11 | Acthar | $17 |
| Travere Therapeutics | Meals · 2025-02-06 | None | $25 |
| Novartis Pharmaceuticals | Meals · 2025-01-28 | None | $20 |
| Calliditas Therapeutics US | Meals · 2025-01-23 | Tarpeyo | $21 |
| Mallinckrodt Hospital Products | Meals · 2025-01-15 | Acthar | $35 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $774
| Fresenius USA Marketing | Velphoro | $200 | 10 payments
|
| Amgen | Krystexxa | $160 | 9 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $98 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $88 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $63 | 3 payments
|
| Novo Nordisk | Ozempic | $49 | 2 payments
|
| Ardelyx | Ibsrela | $48 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $44 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $24 | 1 payment
|
2023: $847
| AstraZeneca Pharmaceuticals LP | Farxiga | $212 | 11 payments
|
| Fresenius USA Marketing | Velphoro | $147 | 8 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $75 | 4 payments
|
| Alexion Pharmaceuticals | Ultomiris | $57 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $56 | 3 payments
|
| Amgen | Epogen | $41 | 2 payments
|
| Travere Therapeutics | None | $41 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $39 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $39 | 2 payments
|
| Vifor Pharma | Veltassa | $36 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $29 | 1 payment
|
| Genzyme | Fabrazyme | $23 | 1 payment
|
| Kyowa Kirin | None | $19 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $17 | 1 payment
|
| GlaxoSmithKline | Benlysta | $16 | 1 payment
|
2022: $642
| Vifor Pharma | Veltassa | $120 | 8 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $72 | 3 payments
|
| GlaxoSmithKline | Benlysta | $70 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $66 | 4 payments
|
| Amgen | Parsabiv | $56 | 2 payments
|
| Travere Therapeutics | None | $45 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $44 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $37 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $37 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $32 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $27 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $22 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $14 | 1 payment
|
2021: $321
| Amgen | Parsabiv | $76 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $73 | 4 payments
|
| Aurinia Pharma U.S. | Lupkynis | $49 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $42 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $35 | 2 payments
|
| Vifor Pharma | Veltassa | $31 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $14 | 1 payment
|
2020: $140
| Relypsa | Veltassa | $64 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $38 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $19 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $18 | 1 payment
|
2019: $77
| AstraZeneca Pharmaceuticals LP | Lokelma | $38 | 2 payments
|
| Relypsa | Veltassa | $20 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $19 | 1 payment
|
Professional record
- NPI
- 1124058805
- Licence
- CA A79279California A79279: Current · expires 2028-02-29
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- 18055 Idalyn Dr, Los Gatos, CA, 95033
- NPI first listed
- 2006-07-05
- NPI last updated
- 2014-02-21
This is when the NPI record was last certified, not a medical board exam.